Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA 02115
(866) 408-DFCI (3324)
Center For Hematologic Oncology
The Center for Hematologic Oncology provides outstanding care for patients with all types of hematologic malignancies and aims to advance the field through innovative clinical and basic research. In addition, the center provides unique educational opportunities for physicians, medical students, postdoctoral fellows, and other health care professionals. The center is comprised of faculty involved in clinical research, clinical care, and basic laboratory studies and is informally subdivided into five programs: Leukemia, Lymphoma, Multiple Myeloma, Stem Cell/Bone Marrow Transplant/Immunotherapy, and Waldenström's Macroglobulinemia.
Leukemia Program
Our Services
The Adult Leukemia Program provides virtually all services required by patients with acute leukemia and related disorders. These include:
* evaluation and diagnosis of individuals with any type of bone-marrow disorder, including acute and chronic leukemias, myeloproliferative disorders, and myelodysplastic syndromes
* evaluation and diagnosis of patients with unexplained anemia, or abnormal white blood or platelet counts
* development and implementation of a personalized treatment plan, ranging from standard supportive care to intensive chemotherapy for acute leukemia
* access to new therapies through clinical research protocols
* comprehensive bone marrow transplantation services
* support services
Clinical Research
The clinical research mission of the Adult Leukemia Program is to develop and bring new and better therapies to patients. At any given time, the program offers patients a wide array of opportunities to participate in clinical research studies relating to all stages and types of leukemia and related disorders. Patients have access to trials that originate within Dana-Farber/Brigham and Women's Cancer Center and other Harvard-affiliated institutions, those sponsored by private industry, as well as those that are part of a collaborative effort, such as the Cancer and Leukemia Group B, of which the program is a member.
Physician-researchers within the program are currently involved in a number of exciting avenues of investigation, which include targeted therapies aimed at making cancer treatment more specific and less toxic. These include:
* immunotherapy for acute leukemia and myelodysplasia involving agents such as interleukin-2 and autologous vaccines
* integrating antibody-based therapy against leukemia cells with standard chemotherapy
* promoting the differentiation or normal growth of bone marrow cells in patients with myelodysplasia
* working with molecules that interrupt the normal cascade of biochemical signals within the cell that promote the growth of leukemia
© 2001 – 2009, Dana-Farber Cancer Institute
Votes:9
Comments: 0